• Product nameAnti-CD96 antibody [NK92.39]
    See all CD96 primary antibodies
  • Description
    Mouse monoclonal [NK92.39] to CD96
  • Tested applicationsSuitable for: Blocking, Functional Studies, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human NK92 cells



Our Abpromise guarantee covers the use of ab81717 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies
Flow Cyt
  • Application notesBL: ab81717 blocks binding of soluble poliovirus receptor (PVR) to NK92 cells.
    Flow Cyt: Use at a starting dilution of 1/50. Optimal dilutions will depend on the detection system used.
    FuncS: Use at an assay dependent dilution.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionMay be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.
    • Tissue specificityExpressed on normal T-cell lines and clones, and some transformed T-cells, but no other cultured cell lines tested. It is expressed at very low levels on activated B-cells.
    • Involvement in diseaseDefects in CD96 are a cause of C syndrome (CSYN) [MIM:211750]; also called Opitz trigonocephaly syndrome. This syndrome is characterized by trigonocephaly and associated anomalies, such as unusual facies, wide alveolar ridges, multiple buccal frenula, limb defects, visceral anomalies, redundant skin, psychomotor retardation and hypotonia. Note=A chromosomal aberration involving CD96 has been found in a patient with C syndrome. Translocation t(3;18)(q13.13;q12.1). CD96 gene was located at the 3q13.13 breakpoint. Precise structural analysis around the breakpoint showed that the gene was disrupted by the translocation in exon 5, probably leading to premature termination or loss of expression of CD96 protein. No gene was detected at the chromosome 18 breakpoint.
      Defects in CD96 are a cause of C-like syndrome (CLSYN) [MIM:605039]; also called Opitz trigonocephaly-like syndrome. The C-like syndrome seems to be a severe form of the C syndrome. It is controversial whether there is (1) a gradient of spectrum in the C syndrome, from the mild form (C syndrome) to the severe form (C-like syndrome), or (2) genetic heterogeneity among the patients with the C syndrome.
    • Sequence similaritiesContains 1 Ig-like C2-type (immunoglobulin-like) domain.
      Contains 2 Ig-like V-type (immunoglobulin-like) domains.
    • Developmental stageExpressed at low levels on peripheral T-cells and is strongly up-regulated after activation, peaking 6 to 9 days after the activating stimulus.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD96 antibody
      • CD96 molecule antibody
      • Cell surface antigen CD96 antibody
      • DKFZp667E2122 antibody
      • MGC22596 antibody
      • T cell activated increased late expression protein antibody
      • T cell activation, increased late expression antibody
      • T cell surface protein tactile precursor antibody
      • T cell-activated increased late expression protein antibody
      • T-cell surface protein tactile antibody
      • TACT_HUMAN antibody
      • Tactile antibody
      see all

    References for Anti-CD96 antibody [NK92.39] (ab81717)

    ab81717 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab81717.
    Please use the links above to contact us or submit feedback about this product.